Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 30 2022 - 8:50PM
Business Wire
Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced the pricing of an underwritten public offering of
6,700,000 shares of its common stock at a price to the public of
$12.00 per share. The gross proceeds from the offering to Aura are
expected to be $80.4 million, before deducting underwriting
discounts and commissions and other offering expenses. The offering
is expected to close on or about December 5, 2022, subject to
customary closing conditions. In addition, Aura has granted the
underwriters a 30-day option to purchase up to 1,005,000 additional
shares of common stock at the public offering price, less the
underwriting discount.
SVB Securities, Cowen and Evercore ISI are acting as joint
bookrunning managers for the offering and JMP Securities, a
Citizens Company, and BTIG are acting as co-managers for the
offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (the “SEC”) on November 1,
2022 and declared effective by the SEC on November 7, 2022. The
offering is being made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and accompanying
prospectus relating to the offering has been filed with the SEC and
is available on the SEC’s website at www.sec.gov. A final
prospectus supplement and accompanying prospectus will be filed
with the SEC. When available, copies of the final prospectus
supplement and the accompanying prospectus may also be obtained by
contacting SVB Securities LLC, Attention: Syndicate Department, 53
State Street, 40th Floor, Boston, MA 02109, by telephone at (800)
808-7525, ext. 6105, or by email at syndicate@svbsecurities.com;
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus
Department, by telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com; or Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, New York 10055; by telephone at (888) 474-0200, or by
email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar;
AU-011), consists of a virus-like particle conjugated with an
anti-cancer agent. Bel-sar is designed to selectively target and
destroy cancer cells and activate the immune system with the
potential to create long-lasting anti-tumor immunity. Bel-sar is
currently in development for ocular cancers, and Aura has initiated
a global Phase 3 trial evaluating first-line treatment of choroidal
melanoma, a vision- and life-threatening form of eye cancer where
standard of care with radiotherapy leaves patients with severe
comorbidities, including major vision loss. Aura plans to pursue
development of bel-sar across its ocular oncology franchise
including for the treatment of patients with choroidal metastasis.
In addition, leveraging Aura’s technology platform, Aura is
developing bel-sar more broadly across multiple cancers, including
in patients with non-muscle invasive bladder cancer (NMIBC). Aura
is headquartered in Boston, MA.
Forward-Looking Statements Various statements in this
release concerning the timing and completion of the public offering
on the anticipated terms or at all may constitute forward-looking
statements for the purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995, as amended, and
other federal securities laws. All such forward-looking statements
are based on management’s current expectations of future events and
are subject to a number of substantial risks and uncertainties,
many of which are outside Aura’s control, that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include fluctuations in Aura’s stock price, changes
in market conditions and satisfaction of customary closing
conditions related to the public offering, as well as those risks
more fully discussed in the section entitled "Risk Factors" in the
prospectus supplement and registration statement referenced above,
Aura’s Annual Report on Form 10-K for the year ended December 31,
2021, filed on March 23, 2022 with the SEC and subsequent filings
with the SEC including our Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. There can be no assurance that Aura
will be able to complete the public offering on the anticipated
terms. Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of
the date made, and Aura undertakes no obligation to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise, unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221130006201/en/
Investors and Media:
Alex Dasalla Head of Investor Relations and Corporate
Communications adasalla@aurabiosciences.com
Argot Partners Matthew DeYoung aura@argotpartners.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024